GO:0031695 alpha-2B adrenergic receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031695 (alpha-2B adrenergic receptor binding) is a molecular function defined as binding to an alpha-2B adrenergic receptor.
• The alpha-2B adrenergic receptor (ADRA2B) is one of three alpha-2 adrenergic receptor subtypes (A, B, C) with distinct pharmacological profiles.
• Binding to ADRA2B is involved in presynaptic inhibition of neurotransmitter release and central nervous system functions.
• The term is relevant to cardiovascular, metabolic, and neurological research, as well as to studies of receptor trafficking and down-regulation [1,5].
• Key experimental approaches include knockout mice, subtype-selective antagonists, and molecular docking [4,6].
• Dysregulation of alpha-2B adrenergic receptor binding may contribute to hypertension, depression, and other disorders [2,4].
Description
GO:0031695, alpha-2B adrenergic receptor binding, is a molecular function term in the Gene Ontology that describes the binding to an alpha-2B adrenergic receptor. This term is part of the broader class of alpha-adrenoceptor subtypes, which mediate the effects of catecholamines such as norepinephrine and epinephrine. The alpha-2B adrenergic receptor (encoded by the ADRA2B gene) is a G protein-coupled receptor that plays critical roles in presynaptic autoinhibition and heteroinhibition of neurotransmitter release, as well as in central nervous system functions. Understanding the binding properties of this receptor is essential for elucidating its physiological and pharmacological roles. Researchers study alpha-2B adrenergic receptor binding to develop subtype-selective drugs and to understand receptor regulation, trafficking, and signaling [1,3,4]. The term is particularly important because the three alpha-2 adrenergic receptor subtypes (A, B, C) exhibit distinct tissue distributions and functions, and subtype-selective ligands are valuable tools for dissecting these roles. Moreover, the alpha-2B subtype has been implicated in processes such as cell surface transport, down-regulation, and modulation by melatonin [1,5,6]. Thus, GO:0031695 provides a framework for annotating gene products that interact with this receptor, facilitating functional genomics and drug discovery.
alpha-2B adrenergic receptor binding At A Glance
| GO ID | GO:0031695 |
|---|---|
| GO term | alpha-2B adrenergic receptor binding |
| Ontology | molecular_function |
| Synonym | alpha-2B adrenergic receptor ligand |
| Major function | Binding to an alpha-2B adrenergic receptor |
| Related receptor | ADRA2B (alpha-2B adrenergic receptor) |
| Related subtypes | ADRA2A, ADRA2C |
| Relevance | Neurotransmission, cardiovascular regulation, drug discovery |
What Is GO:0031695?
The Gene Ontology term GO:0031695, alpha-2B adrenergic receptor binding, is defined as the binding to an alpha-2B adrenergic receptor. It is a molecular function term that describes the interaction between a ligand or protein and the alpha-2B adrenergic receptor (ADRA2B). This binding event is a key step in receptor activation or modulation, and it is distinct from binding to other alpha-2 adrenergic receptor subtypes such as alpha-2A or alpha-2C [2,7].
Why Is alpha-2B adrenergic receptor binding Important in Cell Biology?
Alpha-2B adrenergic receptor binding is important because it mediates key physiological responses to catecholamines, including modulation of neurotransmitter release, vascular tone, and central nervous system activity [2,4]. The alpha-2B subtype is distinct from other alpha-2 subtypes in its pharmacology and tissue distribution, and it has been implicated in processes such as receptor down-regulation and cell surface transport [1,5]. Understanding this binding event is crucial for developing subtype-selective drugs and for interpreting genetic and pharmacological studies.
• Mediates presynaptic inhibition of neurotransmitter release in the central and peripheral nervous systems.
• Involved in cardiovascular regulation, including blood pressure control.
• Target for subtype-selective antagonists used in research and potential therapeutics.
• Plays a role in receptor trafficking and down-regulation, affecting cellular responsiveness [1,5].
• Modulated by interactions with other proteins such as GGA1 and GGA2 [1,3].
• Relevant to neurological and psychiatric disorders, including depression and anxiety.
• Studied using knockout mice to dissect subtype-specific functions.
• Potential target for melatonin receptor interactions.
• Important for understanding species differences in alpha-2 adrenergic pharmacology.
• Contributes to the broader field of G protein-coupled receptor biology.
Molecular Mechanism of alpha-2B adrenergic receptor binding
Ligand recognition and binding pocket
In simple terms: The alpha-2B receptor has a specific pocket where natural ligands like norepinephrine or synthetic drugs can bind.
The alpha-2B adrenergic receptor (ADRA2B) is a G protein-coupled receptor with a classical seven-transmembrane domain architecture. Binding of agonists or antagonists occurs within a pocket formed by transmembrane helices, and subtype selectivity is determined by specific amino acid residues [2,7]. Molecular docking studies have been used to assess the interaction of melatonin with alpha adrenergic receptors, providing insights into potential binding modes.
Subtype-selective pharmacology
In simple terms: Different drugs can selectively bind to the alpha-2B subtype over other subtypes.
The alpha-2B adrenergic receptor exhibits distinct pharmacological properties compared to alpha-2A and alpha-2C. Subtype-selective antagonists, such as those characterized by Luhrs et al. (2016), allow researchers to specifically probe alpha-2B function in vivo. Bylund (1995) reviewed the pharmacological characteristics that differentiate the subtypes, which is essential for designing selective ligands.
Receptor trafficking and down-regulation
In simple terms: After binding, the receptor can be moved inside the cell or degraded, which controls how long the signal lasts.
Binding to the alpha-2B receptor can trigger down-regulation, a process that reduces receptor number at the cell surface. Heck et al. (1998) demonstrated differential down-regulation of alpha-2 adrenergic receptor subtypes, with alpha-2B showing distinct regulatory properties. Zhang et al. (2016) showed that GGA1 and GGA2 regulate cell surface transport of alpha-2B, indicating that binding and trafficking are tightly linked. A naturally occurring splice variant of GGA1 inhibits anterograde post-Golgi traffic of alpha-2B, further highlighting the role of accessory proteins.
Modulation by heterodimerization and other receptors
In simple terms: The alpha-2B receptor can interact with other receptors, such as melatonin receptors, which can change its binding properties.
Borges et al. (2022) used molecular docking to assess melatonin-alpha adrenergic receptor complexes, suggesting potential cross-talk between melatonin receptors and alpha-2 adrenergic receptors. Dinter et al. (2015) showed that 3-iodothyronamine differentially modulates alpha-2A-adrenergic receptor-mediated signaling, but similar mechanisms may exist for alpha-2B. These interactions can influence ligand binding and downstream signaling.
Physiological consequences of binding
In simple terms: When a ligand binds to alpha-2B, it can change nerve cell activity and blood pressure.
Luhrs et al. (2016) characterized brain alpha-2B-adrenergic receptor function using subtype-selective antagonists and knockout mice, demonstrating its role in modulating behavior and neurotransmitter release. Civantos Calzada and Aleixandre de Artiñano (2001) reviewed alpha-adrenoceptor subtypes and their physiological roles, including cardiovascular effects. Thus, binding to alpha-2B has direct consequences for neuronal and cardiovascular function.
Key Genes Involved in GO:0031695 alpha-2B adrenergic receptor binding
The following genes and proteins are directly involved in or interact with alpha-2B adrenergic receptor binding, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA2B | Encodes the alpha-2B adrenergic receptor, the primary binding target | Central to all studies of GO:0031695; knockout and point mutation models available |
| ADRA2A | Alpha-2A adrenergic receptor subtype | Comparative studies of subtype-specific binding and function [2,7] |
| ADRA2C | Alpha-2C adrenergic receptor subtype | Comparative studies of subtype-specific binding and function [2,7] |
| GNAI1 | G protein alpha subunit that couples to alpha-2 receptors | Mediates downstream signaling upon receptor binding |
| GNAI2 | G protein alpha subunit that couples to alpha-2 receptors | Mediates downstream signaling upon receptor binding |
| GNAI3 | G protein alpha subunit that couples to alpha-2 receptors | Mediates downstream signaling upon receptor binding |
| GGA1 | Golgi-localized gamma adaptin ear-containing ARF-binding protein 1 | Regulates cell surface transport of alpha-2B; binding partner in trafficking [1,3] |
| GGA2 | Golgi-localized gamma adaptin ear-containing ARF-binding protein 2 | Regulates cell surface transport of alpha-2B |
| ARRB1 | Beta-arrestin 1 | Involved in receptor desensitization and internalization after binding |
| ARRB2 | Beta-arrestin 2 | Involved in receptor desensitization and internalization after binding |
| GRK2 | G protein-coupled receptor kinase 2 | Phosphorylates activated receptor, promoting arrestin binding |
| GRK3 | G protein-coupled receptor kinase 3 | Phosphorylates activated receptor, promoting arrestin binding |
| PRKACA | Protein kinase A catalytic subunit | Phosphorylates receptor and downstream targets, modulating binding |
| PRKACB | Protein kinase A catalytic subunit beta | Phosphorylates receptor and downstream targets |
| SLC6A2 | Norepinephrine transporter | Regulates synaptic norepinephrine levels, indirectly affecting receptor binding |
| TH | Tyrosine hydroxylase | Rate-limiting enzyme in catecholamine synthesis, affecting ligand availability |
| DBH | Dopamine beta-hydroxylase | Converts dopamine to norepinephrine, affecting ligand availability |
| COMT | Catechol-O-methyltransferase | Degrades catecholamines, affecting ligand availability |
How Is alpha-2B adrenergic receptor binding Regulated?
The binding of ligands to the alpha-2B adrenergic receptor is regulated at multiple levels. Receptor expression and cell surface availability are controlled by trafficking proteins such as GGA1 and GGA2, which mediate anterograde transport from the Golgi [1,3]. Down-regulation of the receptor after prolonged agonist exposure reduces binding sites, as shown for alpha-2 subtypes. Phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent arrestin binding desensitize the receptor, decreasing its ability to bind agonists. Additionally, heterodimerization with other receptors, such as melatonin receptors, may modulate binding affinity. These regulatory mechanisms ensure tight control of alpha-2B signaling.
alpha-2B adrenergic receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRA2B | Hypertension | Knockout mouse, point mutation knock-in |
| ADRA2B | Depression/anxiety | Conditional knockout, overexpression |
| ADRA2B | Metabolic syndrome | Tissue-specific knockout |
| GGA1 | Neurodegeneration (trafficking defects) | Knockout, tagged knock-in [1,3] |
| GGA2 | Cardiovascular trafficking | Knockout, overexpression |
Cardiovascular disorders
Alpha-2B adrenergic receptors are involved in blood pressure regulation and vascular tone. Civantos Calzada and Aleixandre de Artiñano (2001) reviewed the role of alpha-adrenoceptor subtypes in cardiovascular function, noting that alpha-2B receptors contribute to hypertension and other cardiovascular diseases. Genetic variants in ADRA2B have been associated with altered receptor function, potentially influencing disease susceptibility.
Neurological and psychiatric disorders
The alpha-2B adrenergic receptor is expressed in the brain and modulates neurotransmitter release. Luhrs et al. (2016) characterized brain alpha-2B function using knockout mice and subtype-selective antagonists, suggesting a role in behaviors related to anxiety and depression. Dysregulation of alpha-2B binding may contribute to psychiatric conditions, although further research is needed [2,4].
Metabolic and endocrine disorders
Alpha-2 adrenergic receptors influence insulin secretion and glucose homeostasis. While specific studies on alpha-2B are limited, the subtype is expressed in pancreatic islets and may affect metabolic regulation. Dinter et al. (2015) showed that 3-iodothyronamine modulates alpha-2A signaling, indicating potential cross-talk with thyroid hormone pathways that could extend to alpha-2B.
From alpha-2B adrenergic receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of ADRA2B in blood pressure regulation? | ADRA2B knockout mouse |
| How does a specific point mutation affect ligand binding? | Point mutation knock-in (e.g., D79N) |
| Where is ADRA2B expressed and trafficked? | Tagged knock-in (e.g., GFP-ADRA2B) |
| What happens when ADRA2B is overexpressed? | Transgenic overexpression |
| How does GGA1 regulate ADRA2B surface transport? | GGA1 knockout or knockdown [1,3] |
| Can subtype-selective drugs discriminate ADRA2B? | Pharmacological studies with knockout controls |
How to Study the alpha-2B adrenergic receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Binding affinity and receptor density | Ligand screening, subtype selectivity [2,7] |
| Molecular docking | Predicted binding poses and energies | Virtual screening, mechanism |
| Knockout mouse phenotyping | Physiological consequences of receptor absence | Blood pressure, behavior |
| Cell surface biotinylation | Receptor levels at plasma membrane | Trafficking studies [1,3] |
| Immunofluorescence | Subcellular localization | Transport and internalization |
| Western blot | Total receptor protein levels | Down-regulation studies |
| cAMP assay | Downstream signaling upon binding | Functional coupling |
| Site-directed mutagenesis | Effect of specific residues on binding | Binding pocket mapping |
Radioligand binding assays
Radioligand binding assays are the gold standard for measuring alpha-2B adrenergic receptor binding affinity and density. Using subtype-selective radioligands, researchers can quantify binding parameters (Kd, Bmax) in membrane preparations from cells or tissues [2,7]. This method is essential for characterizing novel ligands and for comparing subtypes.
Molecular docking and computational modeling
Molecular docking studies, such as those by Borges et al. (2022), predict how ligands interact with the alpha-2B receptor binding pocket. These in silico approaches guide mutagenesis experiments and drug design, and they can assess binding modes for compounds like melatonin.
Knockout and transgenic mouse models
Genetically modified mice, including ADRA2B knockout and subtype-selective antagonist studies, are used to dissect the physiological roles of alpha-2B binding in vivo. These models allow researchers to link binding events to behavioral and cardiovascular outcomes.
Cell surface biotinylation and trafficking assays
Cell surface biotinylation and immunofluorescence are used to measure the amount of alpha-2B receptor at the plasma membrane, which reflects binding capacity. Zhang et al. (2016, 2019) used these methods to show that GGA proteins regulate alpha-2B transport [1,3].
How CRISPR Can Be Used to Study GO:0031695 alpha-2B adrenergic receptor binding
Knockout
CRISPR knockout of ADRA2B can eliminate alpha-2B adrenergic receptor binding, providing a clean background to study subtype-specific functions. Knockout cell lines and mice are valuable for validating subtype-selective drugs and for identifying compensatory mechanisms.
Point Mutation
Point mutations in ADRA2B can be introduced to mimic naturally occurring variants or to probe the binding pocket. For example, mutations in transmembrane residues can alter ligand affinity, as demonstrated by pharmacological studies. CRISPR point mutation models allow precise structure-function analysis.
Knock-in
Knock-in of tagged ADRA2B (e.g., GFP or HA) enables real-time tracking of receptor trafficking and binding in live cells. This approach has been used to study GGA-mediated transport of alpha-2B [1,3]. Knock-in models can also express humanized receptors for drug testing.
Overexpression
Overexpression of ADRA2B via CRISPR activation or transgene delivery increases receptor density, enhancing binding signals for biochemical assays. Overexpression models are useful for studying down-regulation and desensitization.
How EDITGENE Supports alpha-2B adrenergic receptor binding Research
Researchers studying alpha-2B adrenergic receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, trafficking, or downstream signaling. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous investigation of GO:0031695 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for alpha-2B adrenergic receptor binding research.
Frequently Asked Questions About alpha-2B adrenergic receptor binding
What is GO:0031695?
GO:0031695 is the Gene Ontology term for alpha-2B adrenergic receptor binding, defined as binding to an alpha-2B adrenergic receptor.
What genes are involved in alpha-2B adrenergic receptor binding?
The primary gene is ADRA2B, which encodes the receptor. Interacting proteins include GGA1, GGA2, and G protein subunits [1,3].
What is the function of alpha-2B adrenergic receptor binding?
It mediates cellular responses to catecholamines, including presynaptic inhibition of neurotransmitter release and cardiovascular regulation [2,4].
How is alpha-2B adrenergic receptor binding studied?
Common methods include radioligand binding assays, molecular docking, knockout mice, and cell surface biotinylation [1,4,6].
What diseases are associated with alpha-2B adrenergic receptor binding?
It has been implicated in hypertension, depression, and metabolic disorders [2,4].
What are the subtypes of alpha-2 adrenergic receptors?
There are three subtypes: alpha-2A, alpha-2B, and alpha-2C, encoded by ADRA2A, ADRA2B, and ADRA2C, respectively [2,7].
How does GGA1 regulate alpha-2B adrenergic receptor binding?
GGA1 mediates anterograde transport of the receptor to the cell surface, affecting the amount available for binding [1,3].
Can CRISPR be used to study alpha-2B adrenergic receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting receptor function.
What is the role of alpha-2B adrenergic receptor in the brain?
It modulates neurotransmitter release and has been implicated in behaviors related to anxiety and depression.
Where can I find validated antibodies for alpha-2B adrenergic receptor?
Commercial antibodies are available, but validation is recommended; EDITGENE can provide knockout cell lines for antibody validation.
Conclusion
GO:0031695, alpha-2B adrenergic receptor binding, is a critical molecular function that underlies the physiological actions of catecholamines in the nervous and cardiovascular systems. Through the use of advanced CRISPR models, researchers can precisely dissect the mechanisms and disease relevance of this binding event. EDITGENE offers a full suite of services to accelerate discovery in this field.
References
- 1. Zhang M et al.. 2016. Regulation of α(2B)-Adrenergic Receptor Cell Surface Transport by GGA1 and GGA2.. Sci Rep 6:37921 PMID: 27901063
- 2. Civantos Calzada B et al.. 2001. Alpha-adrenoceptor subtypes.. Pharmacol Res 44(3):195-208 PMID: 11529686
- 3. Zhang M et al.. 2019. A Naturally Occurring Splice Variant of GGA1 Inhibits the Anterograde Post-Golgi Traffic of α(2B)-Adrenergic Receptor.. Sci Rep 9(1):10378 PMID: 31316103
- 4. Luhrs L et al.. 2016. Function of brain α(2B)-adrenergic receptor characterized with subtype-selective α(2B) antagonist and KO mice.. Neuroscience 339:608-621 PMID: 27751959
- 5. Heck DA et al.. 1998. Differential down-regulation of alpha-2 adrenergic receptor subtypes.. Life Sci 62(17-18):1467-72 PMID: 9585120
- 6. Borges VG et al.. 2022. Assessment of melatonin-alpha adrenergic receptor complexes by molecular docking analysis.. Braz J Biol 82:e261624 PMID: 35920463
- 7. Bylund DB. 1995. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes.. Ann N Y Acad Sci 763:1-7 PMID: 7677317
- 8. Dinter J et al.. 2015. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.. J Mol Endocrinol 54(3):205-16 PMID: 25878061
